Targeting TAMs by inhibiting CCR2 decreased the tumor-initiating cells, resulting in metastasis inhibition and enhancement of the anti-tumor T cell responses in pancreatic tumor and liver cancer [196–198]. This evidence concerns the gene CCR2 and neoplasm.